One Shot, Two Years of Lower Cholesterol: Scribe’s CRISPR Gene Therapy Begins Human Trials
Scribe Therapeutics (SCTX) presented data at AHA 2026 showing its gene therapy STX-1150 maintained LDL cholesterol control for two years in non-human primates. The therapy uses epigenetic gene silencing to target PCSK9. Separately, Scribe's STX-1200, a CRISPR-based LPA gene editor, showed durable Lp(a) reduction in preclinical models. Novartis' pelacarsen failed to reduce cardiovascular events in a Phase 3 trial, impacting competitors.
How this was made
The 30-second read
Why it matters
The presented data represent the first public disclosure of durable LDL‑C control from an epigenetic approach, a potential breakthrough in cardiovascular treatment.
Market read
New preclinical results could drive speculative buying in SCTX and affect the broader biotech sector focused on gene‑editing technologies.
What to watch
regulatory pathway and large‑scale manufacturing challenges could delay commercialization
Background
Scribe Therapeutics, co‑founded by Jennifer Doudna, is a clinical‑stage biotech developing epigenetic CRISPR therapies for cholesterol and lipoprotein(a).
Ticker impact
Scribe Therapeutics presented first-in-human Phase 1 data showing its CRISPR epigenetic therapy STX-1150 achieved two‑year LDL‑C control in primates, a novel durable cholesterol treatment.
potential upside as market prices in durable cholesterol‑lowering results
Durable LDL reduction and safety signals address a major unmet need; early data often trigger speculative buying in biotech.
Market effects
could spark renewed interest in epigenetic and CRISPR‑based cardiovascular therapies
U.S. biotech sector may see modest gains
may influence global cholesterol‑drug development pipelines
Counterpoint
early-stage data may not translate to human efficacy; risk of over‑optimism
Key entities
- companyScribe Therapeutics Inc.
US‑listed biotech developing CRISPR‑based epigenetic therapies
- personJennifer Doudna
Nobel laureate and co‑founder of Scribe Therapeutics
